Double-Layered Hollow Mesoporous Cuprous Oxide Nanoparticles for Double Drug Sequential Therapy of Tumors

Double-Layered Hollow Mesoporous Cuprous Oxide Nanoparticles for Double Drug Sequential Therapy of Tumors

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 28 vom: 10. Juli, Seite e2313212
1. Verfasser: Li, Zongheng (VerfasserIn)
Weitere Verfasser: Yang, Jing, Ren, Bin, Fan, Qingdeng, Huang, Lin, Guo, Shuai, Zhou, RuiLong, Chen, Sijin, Feng, Jie, Yan, Chenggong, Chen, Xiaoyuan, Shen, Zheyu
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article CSC‐enriched tumors cancer stem cells (CSCs) double drug sequential therapy (DDST) double layered hollow mesoporous cuprous oxide nanoparticles (DL‐HMCONs) generic drug delivery system (DDS) Camptothecin XT3Z54Z28A Copper 789U1901C5 mehr... cuprous oxide T8BEA5064F Tretinoin 5688UTC01R Antineoplastic Agents Drug Carriers
Beschreibung
Zusammenfassung:© 2024 Wiley‐VCH GmbH.
Cancer stem cells (CSCs) are one of the determinants of tumor heterogeneity and are characterized by self-renewal, high tumorigenicity, invasiveness, and resistance to various therapies. To overcome the resistance of traditional tumor therapies resulting from CSCs, a strategy of double drug sequential therapy (DDST) for CSC-enriched tumors is proposed in this study and is realized utilizing the developed double-layered hollow mesoporous cuprous oxide nanoparticles (DL-HMCONs). The high drug-loading contents of camptothecin (CPT) and all-trans retinoic acid (ATRA) demonstrate that the DL-HMCON can be used as a generic drug delivery system. ATRA and CPT can be sequentially loaded in and released from CPT3ATRA3@DL-HMCON@HA. The DDST mechanisms of CPT3@ATRA3@DL-HMCON@HA for CSC-containing tumors are demonstrated as follows: 1) the first release of ATRA from the outer layer induces differentiation from CSCs with high drug resistance to non-CSCs with low drug resistance; 2) the second release of CPT from the inner layer causes apoptosis of non-CSCs; and 3) the third release of Cu+ from DL-HMCON itself triggers the Fenton-like reaction and glutathione depletion, resulting in ferroptosis of non-CSCs. This CPT3@ATRA3@DL-HMCON@HA is verified to possess high DDST efficacy for CSC-enriched tumors with high biosafety
Beschreibung:Date Completed 12.07.2024
Date Revised 12.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202313212